商业胶原基支架在骨再生中的重要回顾:Infuse®骨移植的功能特性和临床证据。

IF 5.2 3区 医学 Q1 ENGINEERING, BIOMEDICAL
Niki Karipidou, John Paul Muller Gorley, Chrysoula Katrilaka, Chris Manglaris, Anastasios Nektarios Tzavellas, Maria Pitou, Angeliki Cheva, Nikolaos Michailidis, Eleftherios E Tsiridis, Theodora Choli-Papadopoulou, Amalia Aggeli
{"title":"商业胶原基支架在骨再生中的重要回顾:Infuse®骨移植的功能特性和临床证据。","authors":"Niki Karipidou, John Paul Muller Gorley, Chrysoula Katrilaka, Chris Manglaris, Anastasios Nektarios Tzavellas, Maria Pitou, Angeliki Cheva, Nikolaos Michailidis, Eleftherios E Tsiridis, Theodora Choli-Papadopoulou, Amalia Aggeli","doi":"10.3390/jfb16090313","DOIUrl":null,"url":null,"abstract":"<p><p>This review article provides a comprehensive evaluation of Infuse<sup>®</sup> and InductOs<sup>®</sup>, two ground-breaking recombinant human Bone Morphogenetic Protein-2 (rhBMP-2)-based bone graft products, focusing on their tissue-level regenerative responses, clinical applications, and associated costs. Preclinical and clinical studies demonstrate that rhBMP-2 induces strong osteoinductive activity, effectively promoting mesenchymal stem cell differentiation and vascularized bone remodeling. While generally well-tolerated, these osteoinductive effects are dose-dependent, and excessive dosing or off-label use may result in adverse outcomes, such as ectopic bone formation or soft tissue inflammation. Histological and imaging analyses in craniofacial, orthopedic, and spinal fusion models confirm significant bone regeneration, positioning rhBMP-2 as a viable alternative to autologous grafts. Notably, advances in delivery systems and scaffold design have enhanced the stability, bioavailability, and targeted release of rhBMP-2, leading to improved fusion rates and reduced healing times in selected patient populations. These innovations, alongside its proven regenerative efficacy, underscore its potential to expand treatment options in cases where autografts are limited or unsuitable. However, the high initial cost, primarily driven by rhBMP-2, remains a critical limitation. Although some studies suggest overall treatment costs might be comparable to autografts when factoring in reduced complications and operative time, autografts often remain more cost-effective. Infuse<sup>®</sup> has not substantially reduced the cost of bone regeneration and presents additional safety concerns due to the rapid (burst) release of growth factors and limited mechanical scaffold support. Despite representing a significant advancement in synthetic bone grafting, further innovation is essential to overcome limitations related to cost, mechanical properties, and controlled growth factor delivery.</p>","PeriodicalId":15767,"journal":{"name":"Journal of Functional Biomaterials","volume":"16 9","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470532/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Critical Review of Commercial Collagen-Based Scaffolds in Bone Regeneration: Functional Properties and Clinical Evidence from Infuse<sup>®</sup> Bone Graft.\",\"authors\":\"Niki Karipidou, John Paul Muller Gorley, Chrysoula Katrilaka, Chris Manglaris, Anastasios Nektarios Tzavellas, Maria Pitou, Angeliki Cheva, Nikolaos Michailidis, Eleftherios E Tsiridis, Theodora Choli-Papadopoulou, Amalia Aggeli\",\"doi\":\"10.3390/jfb16090313\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This review article provides a comprehensive evaluation of Infuse<sup>®</sup> and InductOs<sup>®</sup>, two ground-breaking recombinant human Bone Morphogenetic Protein-2 (rhBMP-2)-based bone graft products, focusing on their tissue-level regenerative responses, clinical applications, and associated costs. Preclinical and clinical studies demonstrate that rhBMP-2 induces strong osteoinductive activity, effectively promoting mesenchymal stem cell differentiation and vascularized bone remodeling. While generally well-tolerated, these osteoinductive effects are dose-dependent, and excessive dosing or off-label use may result in adverse outcomes, such as ectopic bone formation or soft tissue inflammation. Histological and imaging analyses in craniofacial, orthopedic, and spinal fusion models confirm significant bone regeneration, positioning rhBMP-2 as a viable alternative to autologous grafts. Notably, advances in delivery systems and scaffold design have enhanced the stability, bioavailability, and targeted release of rhBMP-2, leading to improved fusion rates and reduced healing times in selected patient populations. These innovations, alongside its proven regenerative efficacy, underscore its potential to expand treatment options in cases where autografts are limited or unsuitable. However, the high initial cost, primarily driven by rhBMP-2, remains a critical limitation. Although some studies suggest overall treatment costs might be comparable to autografts when factoring in reduced complications and operative time, autografts often remain more cost-effective. Infuse<sup>®</sup> has not substantially reduced the cost of bone regeneration and presents additional safety concerns due to the rapid (burst) release of growth factors and limited mechanical scaffold support. Despite representing a significant advancement in synthetic bone grafting, further innovation is essential to overcome limitations related to cost, mechanical properties, and controlled growth factor delivery.</p>\",\"PeriodicalId\":15767,\"journal\":{\"name\":\"Journal of Functional Biomaterials\",\"volume\":\"16 9\",\"pages\":\"\"},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2025-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470532/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Functional Biomaterials\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.3390/jfb16090313\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Functional Biomaterials","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3390/jfb16090313","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

摘要

本文综述了两种突破性的重组人骨形态发生蛋白-2 (rhBMP-2)骨移植产品Infuse®和InductOs®的综合评价,重点介绍了它们的组织水平再生反应、临床应用和相关成本。临床前和临床研究表明,rhBMP-2具有较强的骨诱导活性,可有效促进间充质干细胞分化和血管化骨重塑。虽然通常耐受性良好,但这些骨诱导作用是剂量依赖性的,过量或超说明书使用可能导致不良后果,如异位骨形成或软组织炎症。颅面、骨科和脊柱融合模型的组织学和影像学分析证实了显著的骨再生,将rhBMP-2定位为自体移植物的可行替代方案。值得注意的是,递送系统和支架设计的进步增强了rhBMP-2的稳定性、生物利用度和靶向释放,从而提高了融合率,缩短了特定患者群体的愈合时间。这些创新,加上其已证实的再生功效,强调了其在自体移植物有限或不适合的情况下扩大治疗选择的潜力。然而,主要由rhBMP-2驱动的高初始成本仍然是一个关键限制。虽然一些研究表明,在减少并发症和手术时间的因素下,总体治疗费用可能与自体移植物相当,但自体移植物通常更具成本效益。Infuse®并没有大幅降低骨再生的成本,而且由于生长因子的快速(爆裂)释放和有限的机械支架支持,还存在额外的安全问题。尽管人工骨移植技术取得了重大进展,但要克服成本、机械性能和生长因子输送控制等方面的限制,还需要进一步的创新。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Critical Review of Commercial Collagen-Based Scaffolds in Bone Regeneration: Functional Properties and Clinical Evidence from Infuse® Bone Graft.

This review article provides a comprehensive evaluation of Infuse® and InductOs®, two ground-breaking recombinant human Bone Morphogenetic Protein-2 (rhBMP-2)-based bone graft products, focusing on their tissue-level regenerative responses, clinical applications, and associated costs. Preclinical and clinical studies demonstrate that rhBMP-2 induces strong osteoinductive activity, effectively promoting mesenchymal stem cell differentiation and vascularized bone remodeling. While generally well-tolerated, these osteoinductive effects are dose-dependent, and excessive dosing or off-label use may result in adverse outcomes, such as ectopic bone formation or soft tissue inflammation. Histological and imaging analyses in craniofacial, orthopedic, and spinal fusion models confirm significant bone regeneration, positioning rhBMP-2 as a viable alternative to autologous grafts. Notably, advances in delivery systems and scaffold design have enhanced the stability, bioavailability, and targeted release of rhBMP-2, leading to improved fusion rates and reduced healing times in selected patient populations. These innovations, alongside its proven regenerative efficacy, underscore its potential to expand treatment options in cases where autografts are limited or unsuitable. However, the high initial cost, primarily driven by rhBMP-2, remains a critical limitation. Although some studies suggest overall treatment costs might be comparable to autografts when factoring in reduced complications and operative time, autografts often remain more cost-effective. Infuse® has not substantially reduced the cost of bone regeneration and presents additional safety concerns due to the rapid (burst) release of growth factors and limited mechanical scaffold support. Despite representing a significant advancement in synthetic bone grafting, further innovation is essential to overcome limitations related to cost, mechanical properties, and controlled growth factor delivery.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Functional Biomaterials
Journal of Functional Biomaterials Engineering-Biomedical Engineering
CiteScore
4.60
自引率
4.20%
发文量
226
审稿时长
11 weeks
期刊介绍: Journal of Functional Biomaterials (JFB, ISSN 2079-4983) is an international and interdisciplinary scientific journal that publishes regular research papers (articles), reviews and short communications about applications of materials for biomedical use. JFB covers subjects from chemistry, pharmacy, biology, physics over to engineering. The journal focuses on the preparation, performance and use of functional biomaterials in biomedical devices and their behaviour in physiological environments. Our aim is to encourage scientists to publish their results in as much detail as possible. Therefore, there is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. Several topical special issues will be published. Scope: adhesion, adsorption, biocompatibility, biohybrid materials, bio-inert materials, biomaterials, biomedical devices, biomimetic materials, bone repair, cardiovascular devices, ceramics, composite materials, dental implants, dental materials, drug delivery systems, functional biopolymers, glasses, hyper branched polymers, molecularly imprinted polymers (MIPs), nanomedicine, nanoparticles, nanotechnology, natural materials, self-assembly smart materials, stimuli responsive materials, surface modification, tissue devices, tissue engineering, tissue-derived materials, urological devices.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信